News | May 31, 2021
Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company will be holding 26% of the share capital in each of the solar power generating companies.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Subscribe To Our Newsletter & Stay Updated
